Dupont Capital Management Corp Sells 3,221 Shares of Abbott Laboratories (NYSE:ABT)

Dupont Capital Management Corp decreased its holdings in Abbott Laboratories (NYSE:ABTFree Report) by 2.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 123,835 shares of the healthcare product maker’s stock after selling 3,221 shares during the period. Abbott Laboratories accounts for about 1.2% of Dupont Capital Management Corp’s portfolio, making the stock its 21st biggest holding. Dupont Capital Management Corp’s holdings in Abbott Laboratories were worth $13,631,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Fairfield Bush & CO. purchased a new stake in shares of Abbott Laboratories in the first quarter worth about $131,000. United Bank lifted its position in shares of Abbott Laboratories by 7.2% in the first quarter. United Bank now owns 27,280 shares of the healthcare product maker’s stock worth $3,229,000 after buying an additional 1,826 shares in the last quarter. Mackenzie Financial Corp lifted its position in shares of Abbott Laboratories by 1.9% in the first quarter. Mackenzie Financial Corp now owns 813,253 shares of the healthcare product maker’s stock worth $96,257,000 after buying an additional 15,521 shares in the last quarter. Kinneret Advisory LLC raised its position in Abbott Laboratories by 2.3% during the first quarter. Kinneret Advisory LLC now owns 19,467 shares of the healthcare product maker’s stock valued at $2,304,000 after purchasing an additional 436 shares during the period. Finally, Lumature Wealth Partners LLC raised its position in Abbott Laboratories by 636.2% during the first quarter. Lumature Wealth Partners LLC now owns 2,216 shares of the healthcare product maker’s stock valued at $262,000 after purchasing an additional 1,915 shares during the period. Institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ABT shares. TheStreet upgraded Abbott Laboratories from a “c+” rating to a “b-” rating in a research report on Thursday, December 21st. Barclays upped their price objective on Abbott Laboratories from $133.00 to $141.00 and gave the company an “overweight” rating in a research report on Friday, January 26th. Wells Fargo & Company upped their price objective on Abbott Laboratories from $116.00 to $121.00 and gave the company an “overweight” rating in a research report on Wednesday, December 13th. Raymond James upped their price objective on Abbott Laboratories from $124.00 to $127.00 and gave the company an “outperform” rating in a research report on Thursday, January 25th. Finally, Citigroup upped their target price on Abbott Laboratories from $123.00 to $126.00 and gave the company a “buy” rating in a research note on Thursday, January 25th. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $121.77.

Get Our Latest Research Report on Abbott Laboratories

Abbott Laboratories Stock Down 0.1 %

Shares of NYSE:ABT opened at $112.02 on Wednesday. The company has a quick ratio of 1.16, a current ratio of 1.64 and a debt-to-equity ratio of 0.35. The stock has a market cap of $194.37 billion, a P/E ratio of 34.36, a price-to-earnings-growth ratio of 2.74 and a beta of 0.74. The business’s 50 day moving average is $115.06 and its 200 day moving average is $106.67. Abbott Laboratories has a 52-week low of $89.67 and a 52-week high of $121.64.

Abbott Laboratories (NYSE:ABTGet Free Report) last announced its earnings results on Wednesday, January 24th. The healthcare product maker reported $1.19 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.19. The business had revenue of $10.24 billion for the quarter, compared to analysts’ expectations of $10.19 billion. Abbott Laboratories had a return on equity of 20.65% and a net margin of 14.27%. The business’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.03 EPS. Sell-side analysts predict that Abbott Laboratories will post 4.62 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be issued a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, April 12th. This represents a $2.20 annualized dividend and a dividend yield of 1.96%. Abbott Laboratories’s dividend payout ratio is presently 67.48%.

Insider Activity

In other news, VP John A. Jr. Mccoy sold 472 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $55,932.00. Following the completion of the sale, the vice president now owns 18,760 shares in the company, valued at approximately $2,223,060. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, VP John A. Jr. Mccoy sold 472 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the completion of the transaction, the vice president now owns 18,760 shares in the company, valued at approximately $2,223,060. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Andrea F. Wainer sold 42,500 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $112.50, for a total value of $4,781,250.00. Following the completion of the transaction, the executive vice president now owns 65,027 shares of the company’s stock, valued at approximately $7,315,537.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 56,435 shares of company stock worth $6,451,298. Insiders own 0.47% of the company’s stock.

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Recommended Stories

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABTFree Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.